 buy pt expect direct well indirect benefit tax reform rais
pt analyst stephen anderson full summari
inc buy pt increas pt acquisit practic
fusion better-than-expect ei revenu rate analyst anthoni vendetti full summari
seagat technolog plc stx hold pt dec posit pre-announce analysi suggest price
inc buy pt stay cours manag provid steadi outlook
icr one top pick analyst stephen anderson full summari
can-fit biopharma ltd canf buy pt distribut agreement sign picledenoson three european
cytosorb corpor buy pt preliminari result show record sale analyst jason kolbert
corpor event call maxim salesperson inform
inc cover chokshi ndr lo angel ceo georg kurian tue jan
inc cover jang ndr nyc ceo gari vogel cfo frank decostanzo
dec posit pre-announce analysi suggest
decemb quarter posit pre-announce flat y/i revenu analysi
suggest price pressur recov near-lin hdd
rais price target slightli maintain hold rate
decemb quarter posit pre-announce flat y/i revenu analysi
suggest price pressur recov near-lin hdd stx posit pre-
announc decemb quarter result flat y/i q/q prior
midpoint guidanc ship y/i q/q averag tb/
drive y/i q/q manag call solid demand high capac
storag cloud base environ corrobor signific
acceler eb acceler y/i sept y/i dec tb/
drive ship acceler y/i sept y/i dec gm
rose q/q y/i flat revenu y/i like
revenu less depreci amort year ago impli stx bore
price pressur y/i basi inclin believ price pressur like
result price action taken drive traction high capac drive public cloud
environ especi given note june septemb quarter
main driver overal y/i revenu declin y/i averag
y/i declin enterpris revenu due lack high capac drive
public cloud provid previous
rais price target maintain hold rate given better
guid result tweak estim slightli remain forecast period
specif rais revenu estim
y/i rais jun end revenu estim
y/i given price pressur pre-announce result impli take
gm estim opex y/
came lower midpoint guidanc note manag
provid lower mid-term opex target given data point suggest
stx revenu begin stabil expect materi opex cut rel
alreadi commun slightli higher revenu estim
slightli lower gm unchang opex modestli rais ep
estim correspond ebit margin result
price target increas price target base
multipl ep estim discount back one year
click full note
expect direct well indirect benefit tax
reform rais pt
maintain buy rate rais price
target follow updat ep guidanc yesterday
model direct ep upsid much annual basi
lower corpor tax basi alon believ could addit
upsid acceler buyback
believ extrem cold late decemb earli januari may reduc
februari comp much though still rais
pro forma ep reflect lower tax rate
model direct ep upsid much annual basi
lower corpor tax basi alon believ could addit
upsid acceler buyback yesterday press releas manag said
recent pass feder tax reform would reduc effect tax rate
assum tax reform would serv direct catalyst ep upsid
given dri three-year averag combin effect corpor tax rate
baselin assum combin tax rate feder florida state
base post-reform combin corpor tax rate per manag
guidanc includ company-specif credit deduct estim tax reform
add ep ep annual
moreov believ addit million invest compani
use proce lower corpor tax buy back share estim
share buyback add much ep ep
prior respect estim
believ extrem cold late decemb earli januari may reduc
februari comp much though still rais
pro forma ep reflect lower tax rate estim
coldest decemb nationwid sinc eastern sinc like
hurt casual dine traffic industrywid decemb earli januari evidenc
lacklust preliminari comp dave buster
buy announc yesterday howev still believ underli comp trend remain
robust estim comp run pace better moreov
contend corpor tax reform immedi upsid sale dri
higher-end brand total sale describ detail decemb
compani report although model weather-reduc comp lower
ep estim off-set ep gain
lower corpor tax rate
attract re-entri point icr pullback upwardli revis price target
base sum-of-part valuat weigh mass-market
casual dine concept higher-end fine dine upscal casual concept
franchise/licens incom use base valuat year revis price target
also correspond companywid forward price-to-earnings ratio slightli
compani three-year averag forward ev/ebitda ratio
compani three-year averag ratio
click full note
increas pt acquisit practic
fusion better-than-expect ei revenu rate
announc acquisit practic fusion provid cloud-
base electron health record ehr platform cash
acquisit expect close
believ practic fusion sold revenu impli
revenu run rate expect margin accret
estim compani recently-acquir enterpris inform
system ei busi oper roughli revenu run
rate significantli origin estim
believ attrit ei busi may lower origin project
bottom line would continu buyer due better-than-
expect revenu run rate ei yesterday announc acquisit practic
fusion lower tax rate practic fusion provid ehr solut primarili
small independ practic doctor also sell data collect
monthli patient visit payer life-sci busi view
attract acquisit round compani ambulatori portfolio
potenti posit ehr low-end practic also see cross-
sell opportun busi integr progress specif
revenu cycl manag solut moreov encourag
releas better-than-expect ei financi continu view acquisit
posit believ may success limit attrit ei drive
out-performance higher-than-anticip return invest
practic fusion acquisit yesterday market open announc
definit agreement acquir san francisco-bas practic fusion privat
cash practic fusion offer cloud-bas ehr platform posit
afford solut small independ physician practic compani
support ambulatori practic patient visit per month believ
valuat revenu impli revenu run rate
conserv model increment revenu low end rang
acquisit expect margin accret close
target expect fund acquisit cash balanc
exist credit facil avail
revis estim due acquisit practic fusion better-than-
expect ei financi result increas non-gaap
revenu estim respect due
improv well effect lower assum tax rate lift
non-gaap ep estim
respect well ep estim
respect result chang increas
price target
attract valuat share current trade ev/revenu estim
compar peer averag new price target base
dcf analysi use discount rate perpetu growth rate price
target impli would trade ev/revenu estim
still peer averag
click full note
preliminari result show record sale
cytosorb given guidanc expect earn
compani expect report revenu
sequenti bring full year revenu contribut
cytosorb sale total annual revenu
growth bring cumul number treatment deliv
cytosorb also report cash posit base
current cash burn rate provid runway
howev compani continu expand sale improv margin
particular new manufactur facil set open expect
burn rate decreas compani move toward profit
 refresh ii studi initi soon cytosorb expect
final clinic trial agreement top two site refresh
studi later week enrol begin shortli studi
assess effect intraop cytosorb blood treatment
post-operative acut kidney injuri aki primari endpoint studi
one common advers event patient undergo complex
conclus cytosorb make steadi progress commerci
clinic front strong sequenti sale growth throughout
immin initi refresh ii trial well posit
come year
cytosorb target sepsi clinic situat cytokin
elev cytosorb built upon compani purif technolog
essenti cartridg fill porou polym bead captur
broadli reduc differ kind cytokin inflammatori mediat drive
inflamm million open heart surgeri perform world-wide
annual mani procedur requir extend surgic time heart-lung machin
cardiopulmonari bypass could result increas destruct blood cell
product toxic free hemoglobin cytokin inflammatori substanc
trigger sever inflamm
focu remain clinic progress
 refresh ii studi expect soon fda green light move
forward cytosorb plan initi refresh ii studi compar
cytosorb vs control larg studi trial enrol patient
undergo elect non-emerg open heart surgeri either valv replac
aortic reconstruct hypotherm cardiac arrest control patient receiv
standard care surgeri treatment patient receiv standard
care dual parallel cytosorb cartridg heart-lung machin bypass circuit
intend reduc toxic inflammatori mediat renal toxin
plasma free hemoglobin activ complement surgeri
remind refresh studi evalu cytosorb treat
inflamm critically-il cardiac surgeri patient cytosorb demonstr
statist signific reduct pfhb level hour reduct
reduc hour reduct time also
identifi valv replac surgeri cardiac procedur highest risk
peak pfhb gener data demonstr cardiac surgeri valv
replac patient requir cardiac bypass releas high level
plasma free hemoglobin pfhb trigger sever post-op inflamm
lead organ failur
click full note
distribut agreement sign picledenoson three
week announc enrol first patient
acrobat studi piclidenoson ra can-fit announc distribut
agreement gebro hold gmbh distribut spain switzerland
austria upon regulatori approv
agreement come double-digit royalti percentag well
up-front mileston payment addit payment total
receiv can-fit complet certain regulatori sale launch
gebro hold gmbh privat headquart austria strong
focu pain rheumatolog compani also maintain commerci
oper switzerland well spain rank
rheumatolog pain make strateg partner piclodenoson
recal piclidenoson recent initi acrobat studi
enrol ra patient piclidenoson oral pill
given twice daili vs methotrex soc medic weekli placebo
primari endpoint chang diseas activ week treatment
studi durat week provid addit long-term efficaci
safeti data second studi psoriasi expect initi
earli studi evalu piclidenoson vs placebo otezla
conclus sign distribut agreement strateg partner
necessari step eventu commerci piclidenoson
provid non-dilut capit compani face increas cost
target adenosin receptor overexpress
inflammatori cell cancer cell low express normal
cell differenti express level make ideal target drug
develop autoimmun diseas cancer can-fit target
drug piclidenoson namodenoson modul key signal
protein subsequ induc cell death reduct inflammatori cytokin
importantli protein serv biomark patient screen
express can-fit determin patient like respond
treatment can-fit develop drug target sever indic
nash non-alcohol steatohepat erectil dysfunct
can-fit expand platform target cytokin releas syndrom car-
well addit immunotherapi induc
go pivot ra psoriasi piclidenoson lead program
studi ra octob program psoriasi initi
earli studi piclidenoson given twice daili patient
achiev howev patient prior
system treatment piclidenoson superior methotrex trial
evalu piclidenoson non-inferior methotrex
click full note
stay cours manag provid
steadi outlook icr one top pick
maintain buy rate price target del follow
manag present icr confer orlando earlier today
manag indic comfort decemb guidanc
impli comp quarter
manag anticip mid-single-digit comp growth unit growth
well signific benefit lower corpor tax rate
maintain ep estim
though rais ep estim reflect
outlook acceler share buyback post-tax reform
manag indic comfort decemb guidanc
impli comp quarter particularli encourag
hear transaction/traff growth posit decemb earli januari
even launch aggress discount
salvo tier valu menu given menu price increas
modest transact growth continu posit mix shift toward higher-ticket
dinner item remain confid forecast blend comp growth
vs street mean
guidanc mid-single-digit comp growth unit growth similar
record argu taco everyday balanc menu
approachsupport recent expand buck menu low
end includ beverag plato platter high endwil help
sustain traffic ticket also announc would launch
mobil order app nationwid model same-restaur sale lift
annual basi mobil order primarili
increas averag order size also believ could benefit recent
legal recreat marijuana use california given compani
locat locat open hour per
day manag said today call del uniqu situat benefit
regard unit growth said anticip anoth year mid-single-digit unit
growth focu fill company-own market western
franchis market southeast stand among restaur
compani announc deceler unit growth
novemb client meet restaur tour manag said expect
acceler expans next year
manag anticip signific benefit lower corpor tax rate
januari icr preview report said reduct corpor tax rate
would add much annual ep els equal although
manag said intend invest increas oper cash flow grow
busi state preview report believ manag
acceler share repurchas base comment made today reflect
increas ep estim
compel valuat share price pullback use
base valuat year three differ valuat methodolog equal
weight forward price-to-earnings multipl base multipl yield
price target forward ev/ebitda multipl base multipl yield
price target forward sale multipl base multipl yield
price target methodolog arriv price target
round
click full note
maxim analyst coverag univers
